石药创新最新公告：控股子公司药物获美国FDA快速通道资格

证券之星08-26 17:17

石药创新(300765.SZ)公告称，公司控股子公司巨石生物研发的首创PD-1/IL-15双特异性融合蛋白SYS6090(JMT108)获美国FDA授予快速通道资格，用于治疗既往经标准系统性治疗后出现疾病进展的微卫星稳定或错配修复功能完整型转移性结直肠癌患者。该资格有助于加快药物开发与审批进程，但最终获批上市仍存在不确定性。

以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2662879146?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-26 17:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2662879146","market":"sh","top_or_hot":-1,"title":"石药创新最新公告：控股子公司药物获美国FDA快速通道资格","media":"证券之星","content":"<html><body><p><a href=\"https://laohu8.com/S/300765\">石药创新</a>(300765.SZ)公告称，公司控股子公司巨石<a href=\"https://laohu8.com/S/000504\">生物</a>研发的首创PD-1/IL-15双特异性融合蛋白SYS6090(JMT108)获美国FDA授予快速通道资格，用于治疗既往经标准系统性治疗后出现疾病进展的微卫星稳定或错配修复功能完整型转移性结直肠癌患者。该资格有助于加快药物开发与审批进程，但最终获批上市仍存在不确定性。</p><p>以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>石药创新最新公告：控股子公司药物获美国FDA快速通道资格</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n石药创新最新公告：控股子公司药物获美国FDA快速通道资格\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-26 17:17 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026082600038205.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>石药创新(300765.SZ)公告称，公司控股子公司巨石生物研发的首创PD-1/IL-15双特异性融合蛋白SYS6090(JMT108)获美国FDA授予快速通道资格，用于治疗既往经标准系统性治疗后出现疾病进展的微卫星稳定或错配修复功能完整型转移性结直肠癌患者。该资格有助于加快药物开发与审批进程，但最终获批上市仍存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。</p>\n\n<a href=\"https://stock.stockstar.com/RB2026082600038205.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"300765","symbol_name":"石药创新","start_time":0,"source_url":"https://stock.stockstar.com/RB2026082600038205.shtml","article_id":"2662879146","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2662879146","pubTimestamp":1787735872,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"石药创新(300765.SZ)公告称，公司控股子公司巨石生物研发的首创PD-1/IL-15双特异性融合蛋白SYS6090(JMT108)获美国FDA授予快速通道资格，用于治疗既往经标准系统性治疗后出现疾病进展的微卫星稳定或错配修复功能完整型转移性结直肠癌患者。该资格有助于加快药物开发与审批进程，但最终获批上市仍存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300765":"石药创新","BK0226":"食品制造"},"translate_title":"The latest announcement of CSPC Innovation: The drug of its holding subsidiary obtained US FDA fast track qualification","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1.5},"content_text":"石药创新(300765.SZ)公告称，公司控股子公司巨石生物研发的首创PD-1/IL-15双特异性融合蛋白SYS6090(JMT108)获美国FDA授予快速通道资格，用于治疗既往经标准系统性治疗后出现疾病进展的微卫星稳定或错配修复功能完整型转移性结直肠癌患者。该资格有助于加快药物开发与审批进程，但最终获批上市仍存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2662879146","isCrawlerRequest":true}